Journal of Clinical Oncology
Articles in this Issue
Oxybutynin for vasomotor symptoms across cancer-related and menopause-associated settings: A systematic review and meta-analysis of randomised control trials and observational studies.
10627 Background: Vasomotor symptoms, including hot flashes, are a frequent and debilitating adverse effect among postmeno...
Phase 1, first-in-human (FIH) study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors.
2041 Background: Patients (pts) with primary high-grade CNS tumors, especially those with glioblastoma (GBM), face poor cl...
Real-world clinical characteristics and outcomes of gastroesophageal cancer treated at a tertiary academic center (2021–2025).
e16085 Background: Gastroesophageal cancer (GEC) remains an aggressive malignancy with high mortality despite therapeutic...
Regorafenib vs. apatinib: An indirect treatment comparison in the treatment of advanced gastric cancer.
e16082 Background: Advanced gastric cancer has a poor prognosis with limited treatment options. The mainstay of treatment...
Using IPOS to trigger advance care planning in outpatient palliative oncology: A multicenter real-world study.
12052 Background: Advance care planning (ACP) is central to high-quality palliative oncology care; however, in Brazil, ACP...
Post-progression treatment strategies and immunotherapy rechallenge sensitivity following chemoradiation and consolidation durvalumab in unresectable stage III NSCLC: The POST-PACIFIC study.
8048 Background: Durvalumab consolidation after platinum-based chemoradiotherapy (CRT) is the standard of care for unresec...
Vaccination patterns among patients receiving ICIs: A practice-informing implementation analysis.
e22673 Background: Vaccination is recommended for patients receiving immune checkpoint inhibitors (ICI), yet historically...
Integrated multi-omics profiling of pulmonary signet ring cell adenocarcinoma to reveal diagnostic markers, immune subtypes, and therapeutic vulnerabilities.
e20026 Background: Pulmonary signet ring cell adenocarcinoma (PSRCA) is a rare, aggressive subset of lung adenocarcinoma w...
Socioeconomic and spatial inequities in U.S. county-level breast cancer mortality, 2018–2023: A Bayesian hierarchical spatial analysis.
e23112 Background: Despite advances in screening and treatment, breast cancer mortality remains uneven across U.S. countie...
Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT.
3644 Background: In patients with proficient mismatch repair (pMMR) locally advanced rectal cancer (LARC), the integration...
A phase Ib/II clinical study of adebrelimab in combination with capecitabine and oxaliplatin for previously untreated patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
e16065 Background: Immune checkpoint inhibitors (ICIs) have dramatically improved survival in various tumor types by preve...
Evaluation of Gemini Pro for primary site prediction in a real-world blinded cohort of 465 patients.
e15002 Background: Artificial intelligence (AI) integration in oncology has transitioned from experimental use to routine...
Digital oncology navigation based on ePROs: Effects on acute healthcare utilization and cost savings in a middle-income country setting.
11111 Background: Oncologic treatment is associated with a high clinical and economic burden. Traditional patient navigati...
Perioperative outcomes and early survival after curative-intent non–small cell lung cancer (NSCLC) resection in a Colombian tertiary center.
e20106 Background: Real-world data on perioperative quality indicators and outcomes after curative-intent NSCLC resection...
Safety and efficacy of a novel PD-L1/4-1BB bispecific antibody QLF31907 in previously-treated patients with advanced melanoma: Results from a phase 2 study.
2527 Background: QLF31907, a bispecific antibody that simultaneously block PD-1/L1 immunosuppressive pathway on cancer cel...
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC.
e23440 Background: Tarlatamab, a DLL3-targeted bispecific T-cell engager (BITE), is approved for small cell lung cancer (S...
Real-world factors associated with early combination therapy initiation in metastatic hormone-sensitive prostate cancer.
e13722 Background: Combination systemic therapy (CST) improves survival in patients with metastatic hormone-sensitive pros...
A real-world data platform for comparative analysis of treatment patterns, costs, and cost-effectiveness among ALK TKIs in advanced NSCLC.
e20688 Background: Real-world evidence (RWE) directly comparing Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK...
Cost-effectiveness analysis in the era of systemic immunotherapy for BCG-naive high-risk non–muscle-invasive bladder cancer in the United States, the United Kingdom, and China.
4598 Background: Non–muscle-invasive bladder cancer (NMIBC) has entered the era of systemic immunotherapy, with randomized...
Efficacy of angiotensin receptor–neprilysin inhibitor (ARNI) for prevention of cancer therapy–related cardiac dysfunction: A meta-analysis of randomized controlled trials.
e24182 Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a clinically significant complication of anticanc...
Emergency presentation and inpatient vulnerability in sinonasal malignancies: National evidence of a diagnostic delay phenotype.
e23248 Background: Sinonasal malignancies are rare, heterogeneous tumors characterized by nonspecific early symptoms and f...
Association of baseline quality of life (QOL) and early death in patients with metastatic renal cell carcinoma (mRCC) in the real-world prospective observational ODYSSEY study.
4559 Background: Baseline QOL has been linked to survival in mRCC therapy clinical trials (Cella, 2024); however, there is...
Differences in outcomes for elderly patients with DLBCL treated at academic vs community programs: A 10-year survival analysis.
7066 Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy that primarily affects older adu...
Impact of synbindin deficiency on immune checkpoint blocker–induced systemic inflammation and multi-organ damage.
12139 Background: Immune-related adverse events (irAEs) are a major safety limitation for the broad application of immune...
Reduction in circulating tumor DNA (ctDNA) in relation to radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC).
8609 Background: PDL1V (PF-08046054) is a novel, first-in-class, PD-L1–directed vedotin antibody-drug conjugate that consi...